<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432021000600005</article-id>
<article-id pub-id-type="doi">10.7399/fh.11693</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamientos biológicos para la psoriasis: coste de los métodos alternativos de dispensación de la medicación en España]]></article-title>
<article-title xml:lang="en"><![CDATA[Biologic treatments for psoriasis: the cost of alternative methods of dispensation of medication in Spain]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calleja-Hernández]]></surname>
<given-names><![CDATA[Miguel Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ventayol-Bosch]]></surname>
<given-names><![CDATA[Pere]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martí-Ragué]]></surname>
<given-names><![CDATA[Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Casañas-Domingo]]></surname>
<given-names><![CDATA[Mónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa-Samarra]]></surname>
<given-names><![CDATA[Jaume]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nieves-Calatrava]]></surname>
<given-names><![CDATA[Diana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Virgen Macarena Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Sevilla ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario Son Espases Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Palma de Mallorca ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Relaciones Institucionales/Market Access  ]]></institution>
<addr-line><![CDATA[Almirall Barcelona]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Pharmalex Spain Market Access Area ]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>45</volume>
<numero>6</numero>
<fpage>323</fpage>
<lpage>328</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432021000600005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432021000600005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432021000600005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Los servicios de farmacia hospitalaria se han adaptado a la pandemia de COVID-19. El objetivo del estudio es determinar las consecuencias económicas de sustituir la dispensación de medicamentos en el servicio de farmacia hospitalaria por otros métodos de dispensación en el contexto de los tratamientos biológicos para la psoriasis en España.  Método: Se evaluaron múltiples escenarios de dispensación, combinando diferentes frecuencias y lugares de dispensación, y frecuencias del seguimiento de telefarmacia. Se incluyeron los medicamentos biológicos autoinyectables para la psoriasis (inhibidores de interleucinas y del factor de necrosis tumoral alfa). Todos los costes (euros de 2020) se consideraron desde la perspectiva del Sistema Nacional de Salud.  Resultados: Considerando la dispensación en la farmacia hospitalaria, la frecuencia de dispensación cada 4 semanas y la telefarmacia en cada administración, el coste anual de dispensación por paciente osciló entre 194,9 &#8364; y 2.088,0 &#8364;. En los diferentes escenarios simulados, los fármacos biológicos que se asociaron a un coste inferior fueron los que se administran de forma más espaciada en el tiempo (cada 12 semanas).  Conclusiones: En la era post-COVID-19, los nuevos modelos de atención farmacéutica hospitalaria que consideran cambios en la dispensación farmacológica y la telefarmacia tendrán consecuencias económicas para el Sistema Nacional de Salud que merecen consideración.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: Hospital pharmacy services have adapted to the COVID-19 pandemic. The aim of the study is to determine the economic consequences of replacing hospital pharmacy dispensation with other dispensing methods in the context of biological treatments for psoriasis in Spain.  Method: Multiple dispensation scenarios were evaluated, combining different dispensation frequencies and sites, and telepharmacy followup intervals. Self-injectable biological medicines for psoriasis (interleukin and tumour necrosis factor alpha inhibitors) were included. All costs (in 2020 euros) were considered from the perspective of the National Health System.  Results: The annual cost of hospital pharmacy-based dispensations every 4 weeks combined with telepharmacy monitoring at each administration ranged from &#8364;194.9 to &#8364;2,088.0 per patient. Across the different simulated scenarios, biological medicines associated with the lowest cost were those administered less frequently (every 12 weeks).  Conclusions In the post-COVID-19 era, new models of hospital pharmaceutical care that include changes in drug dispensation and telepharmacy strategies will have economic consequences for the National Health System that merit consideration.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Prestación de atención de salud]]></kwd>
<kwd lng="es"><![CDATA[Costes de atención sanitaria]]></kwd>
<kwd lng="es"><![CDATA[Psoriasis]]></kwd>
<kwd lng="es"><![CDATA[Terapia biológica]]></kwd>
<kwd lng="es"><![CDATA[Telemedicina]]></kwd>
<kwd lng="en"><![CDATA[Delivery of health care]]></kwd>
<kwd lng="en"><![CDATA[Health care costs]]></kwd>
<kwd lng="en"><![CDATA[Psoriasis]]></kwd>
<kwd lng="en"><![CDATA[Biologic therapy]]></kwd>
<kwd lng="en"><![CDATA[Telemedicine]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morillo-Verdugo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Margusino-Framiñán]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Monte-Boquet]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Morell-Baladrón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barreda-Hernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rey-Piñeiro]]></surname>
<given-names><![CDATA[XM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Posicionamiento de la Sociedad Española de Farmacia Hospitalaria sobre Telefarmacia. Recomendaciones para su implantación y desarrollo]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2020</year>
<volume>44</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>174-81</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="">
<collab>Sociedad Española de Farmacia Hospitalaria</collab>
<source><![CDATA[Proyecto MAPEX: Marco Estratégico en Telefarmacia]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Niznik]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kane-Gill]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of clinical pharmacist services delivered via telemedicine in the outpatient or ambulatory care setting: A systematic review]]></article-title>
<source><![CDATA[Res Social Adm Pharm]]></source>
<year>2018</year>
<volume>14</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>707-17</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<collab>Ministerio de Sanidad</collab>
<article-title xml:lang=""><![CDATA[Orden SND/293/2020, de 25 de marzo, por la que se establecen condiciones a la dispensación y administración de medicamentos en el ámbito del Sistema Nacional de Salud, ante la situación de crisis sanitaria ocasionada por el COVID-19]]></article-title>
<source><![CDATA[Boletín Oficial del Estado]]></source>
<year></year>
<numero>n.º 85</numero>
<issue>n.º 85</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="">
<collab>Sociedad Española de Farmacia Hospitalaria</collab>
<source><![CDATA[Webinar: Nuevos modelos de atención a pacientes y dispensación no presencial: ¿Cómo damos el siguiente paso?]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tortajada-Goitia]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Morillo-Verdugo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Margusino-Framiñán]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Marcos]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Llamazares]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survey on the situation of telepharmacy as applied to the outpatient care in hospital pharmacy departments in Spain during the COVID-19 pandemic]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2020</year>
<volume>44</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>135-40</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Centro de información online de medicamentos de la AEMPS (CIMA)]]></source>
<year>2020</year>
<publisher-name><![CDATA[CIMA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Estadística</collab>
<source><![CDATA[Índice de precios de consumo]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caro González]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Herranz Alonso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pernia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mur Mur]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Fresneda]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Sarobe González]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Facturación interna de los productos finales elaborados por el Servicio de Farmacia Hospitalaria]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2002</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>266-74</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[San José Ruiz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gil Lemus]]></surname>
<given-names><![CDATA[MÁ]]></given-names>
</name>
<name>
<surname><![CDATA[Figuero Echeverría]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atención farmacéutica y envío domiciliario de medicación a pacientes con leucemia mieloide crónica]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2015</year>
<volume>39</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-22</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanz Granda]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
</person-group>
<source><![CDATA[Estudio del coste de la dispensación de la farmacia comunitaria en España]]></source>
<year>2012</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Farmacia Comunitaria (SEFAC)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="">
<collab>Oblikue Consulting</collab>
<source><![CDATA[Base de datos de costes sanitarios y ratios coste-efectividad españoles: eSalud]]></source>
<year>2007</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="book">
<collab>Sociedad Española de Farmacia Hospitalaria</collab>
<source><![CDATA[El valor de la farmacia hospitalaria: documento de información y posicionamiento]]></source>
<year>2016</year>
<publisher-name><![CDATA[SEFH]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caballero-Romero]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Morillo]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Zaragoza-Rascón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jaramillo-Pérez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Del Pozo-Rubio]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis modal de fallos y efectos y análisis de minimización de costes de tres programas de entrega de medicamentos]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2021</year>
<volume>45</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>66-72</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henderson Berg]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Carrasco]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis]]></article-title>
<source><![CDATA[J Drugs Dermatol]]></source>
<year>2017</year>
<volume>16</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>695-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhoi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bessette]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tkaczyk]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nantel]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maslova]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence, and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2017</year>
<volume>7</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaarschmidt]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Umar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Schmieder]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Terris]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Goebeler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Goerdt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient preferences for psoriasis treatments: impact of treatment experience]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol]]></source>
<year>2013</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>187-98</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Centro de Información Farmacoterapéutica del Servizo Galego de Saúde. Informe de Posicionamiento Terapéutico tildrakizumab (Ilumetri®) en el tratamiento de psoriasis en placas]]></source>
<year>2019</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
